About: Ozoralizumab

An Entity of Type: monoclonal antibody, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Ozoralizumab (trade name Nanozora) is a humanized monoclonal antibody designed for the treatment of inflammatory diseases. Ozoralizumab was developed by Pfizer Inc, and now belongs to Ablynx NV. Ablynx has licensed the rights to the antibody in China to . In 2022, ozoralizumab was approved in Japan for the treatment of rheumatoid arthritis.

Property	Value
dbo:abstract	Ozoralizumab (trade name Nanozora) is a humanized monoclonal antibody designed for the treatment of inflammatory diseases. Ozoralizumab was developed by Pfizer Inc, and now belongs to Ablynx NV. Ablynx has licensed the rights to the antibody in China to . In 2022, ozoralizumab was approved in Japan for the treatment of rheumatoid arthritis. (en)
dbo:alternativeName	Nanozora (en)
dbo:casNumber	1167985-17-2
dbo:fdaUniiCode	05ZCK72TXZ
dbo:kegg	D09944
dbo:wikiPageID	33024108 (xsd:integer)
dbo:wikiPageLength	2543 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1122947007 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Pfizer dbr:Rheumatoid_arthritis dbc:Pfizer_brands dbr:Ablynx dbr:Eddingpharm
dbp:atcPrefix	none (en)
dbp:c	1682 (xsd:integer)
dbp:casNumber	1167985 (xsd:integer)
dbp:chemspiderid	none (en)
dbp:h	2608 (xsd:integer)
dbp:kegg	D09944 (en)
dbp:legalStatus	Rx in Japan (en)
dbp:mabType	mab (en)
dbp:n	472 (xsd:integer)
dbp:o	538 (xsd:integer)
dbp:s	12 (xsd:integer)
dbp:source	zu (en)
dbp:tradename	Nanozora (en)
dbp:type	mab (en)
dbp:unii	5 (xsd:integer)
dbp:verifiedfields	changed (en)
dbp:verifiedrevid	458269333 (xsd:integer)
dbp:watchedfields	changed (en)
dbp:wikiPageUsesTemplate	dbt:Antineoplastic-drug-stub dbt:Drugbox dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Fdacite dbt:Monoclonals_for_immune_system dbt:Monoclonal-antibody-stub
dcterms:subject	dbc:Pfizer_brands
gold:hypernym	dbr:Antibody
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody dbo:Drug
rdfs:comment	Ozoralizumab (trade name Nanozora) is a humanized monoclonal antibody designed for the treatment of inflammatory diseases. Ozoralizumab was developed by Pfizer Inc, and now belongs to Ablynx NV. Ablynx has licensed the rights to the antibody in China to . In 2022, ozoralizumab was approved in Japan for the treatment of rheumatoid arthritis. (en)
rdfs:label	Ozoralizumab (en)
owl:sameAs	freebase:Ozoralizumab wikidata:Ozoralizumab https://global.dbpedia.org/id/4ssYZ
prov:wasDerivedFrom	wikipedia-en:Ozoralizumab?oldid=1122947007&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:Ozoralizumab
is dbo:wikiPageRedirects of	dbr:Nanozora
is dbo:wikiPageWikiLink of	dbr:Nanozora dbr:List_of_therapeutic_monoclonal_antibodies
is foaf:primaryTopic of	wikipedia-en:Ozoralizumab